Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Magnesium Sulfate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Recipient : Athenex
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Magnesium sulfate injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia. It reduces striated muscle contractions and blocks peripheral neuromuscular transmission ...
Brand Name : Magnesium Sulfate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2023
Lead Product(s) : Magnesium Sulfate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Recipient : Athenex
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pyridostigmine
Therapeutic Area : Immunology
Study Phase : Approved
Recipient : Milla Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Abbreviated New Drug Application (ANDA) for a generic version of Mestinon (Pyridostigmine Bromide Syrup) 60 mg/5mL, is indicated for symptomatic treatment of myasthenia gravis.
Brand Name : Pyridostigmine Bromide-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2022
Lead Product(s) : Pyridostigmine
Therapeutic Area : Immunology
Highest Development Status : Approved
Recipient : Milla Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Hyloris Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group
Details : Maxigesic IV (a unique combination of 1000 mg paracetamol and 300 mg ibuprofen solution for infusion) is a novel, patented, non-opioid pain treatment, and is being commercialised by Hyloris’ partner AFT...
Brand Name : Maxigesic IV
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 24, 2021
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Hyloris Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?